Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Better Bets vs. SVA Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Sinovac Biotech (SVA)

Market Price (9/30/2025): $0.0 | Market Cap: $0
Sector: Health Care | Industry: Biotechnology

Sinovac Biotech (SVA)

Market Price (9/30/2025): $0.0
Market Cap: $0
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 108%		  
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 42%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 94%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 69%		  
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 108%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 42%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 94%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 69%

Market Valuation

 9/30/2520242023202220212020
Share Price CYE$0.00$6.47$6.47$6.47$6.47$6.47
Market Cap CYE ($ Mil)0.0639.9639.9639.9639.9639.9
Total Debt ($ Mil)136.4299.074.7144.9136.420.3
Total Cash ($ Mil)1,176.311,223.211,312.713,415.31,176.3203.0
Enterprise Value ($ Mil)-1,039.9938.9714.6784.8776.3660.2
Valuation Ratios      
P/S TTM0.00.00.00.00.00.0
P/EBIT TTM0.00.00.00.00.00.0
P/E TTM0.00.00.00.00.00.0
Sector Ratios      
P/S TTM (Sector)3.73.64.04.57.38.1
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.8-3.8
P/E TTM (Sector)-1.9-1.5-1.5-1.3-2.8-4.0
 9/30/25202420232022
Share Price CYE$0.00$6.47$6.47$6.47
Market Cap CYE ($ Mil)0.0639.9639.9639.9
Total Debt ($ Mil)136.4299.074.7144.9
Total Cash ($ Mil)1,176.311,223.211,312.713,415.3
Enterprise Value ($ Mil)-1,039.9938.9714.6784.8
Valuation Ratios    
P/S TTM0.00.00.00.0
P/EBIT TTM0.00.00.00.0
P/E TTM0.00.00.00.0
Sector Ratios    
P/S TTM (Sector)3.73.64.04.5
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3
P/E TTM (Sector)-1.9-1.5-1.5-1.3

Business Description

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; and Split viron pandemic influenza vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
SVA Return0%0%0%0%0%-100%�
Peers Return75%-16%-34%-21%-51%47%-45%
S&P 500 Return16%27%-19%24%23%13%106%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, EDIT, INFIQ, SRNE, STA.
[3] 2025 data is for the year up to 9/29/2025 (YTD)

Better Bets than Sinovac Biotech (SVA)

 SVABetter Performance than SVA
MetricValueIndustry (Biotechnology)
Rev Chg LTM107.5%MDGL (3422.0%), CYTK (2635.7%), KRYS (116.1%), ARWR (2816.2%), NAMS (762.1%)
Rev Chg 3Y Avg110.6%BBIO (1225.0%), CYTK (824.6%), RYTM (137.5%), AXSM (699.5%), CRSP (380.7%)
Op Mgn LTM42.3%UTHR (50.1%), RPRX (79.8%), HALO (57.9%), PTCT (49.1%), CPRX (43.6%)
CFO/Rev LTM93.9%RPRX (104.4%), KURA (150.1%), TBPH (317.4%), TVRD (133.3%)
FCF/Rev LTM68.9%RPRX (104.4%), KURA (147.5%), TBPH (317.1%), TVRD (133.3%)
 SVABetter Performance than SVA
MetricValueAll Other Sectors
Rev Chg LTM107.5%ALAB (163.8%), NBIS (542.6%), CRDO (175.8%), CG (133.3%), SW (163.8%)
Rev Chg 3Y Avg110.6%APO (129.8%), NBIS (160.6%), RIVN (183.6%), IREN (125.3%), QXO (1115.2%)
Op Mgn LTM42.3%NVDA (58.1%), MSFT (45.6%), META (42.9%), V (66.5%), MA (58.0%)
CFO/Rev LTM93.9%RY (135.4%), IBKR (157.8%), NLY (123.7%), XP (145.7%), JXN (103.0%)
FCF/Rev LTM68.9%RY (131.7%), SCHW (79.4%), ARES (82.4%), IBKR (157.2%), WPC (76.3%)

Trade Ideas

Select past trade ideas related to SVA and Biotechnology.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE08312025LNTHLantheusDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-7.8%-7.8%-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025COOCooper CompaniesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.2%0.2%-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.9%5.9%-1.3%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		1.9%1.9%0.0%
UTHR_7312025_Dip_Buyer_FCFYield07312025UTHRUnited TherapeuticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		57.5%57.5%0.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE08312025LNTHLantheusDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-7.8%-7.8%-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025COOCooper CompaniesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.2%0.2%-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.9%5.9%-1.3%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		1.9%1.9%0.0%
UTHR_7312025_Dip_Buyer_FCFYield07312025UTHRUnited TherapeuticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		57.5%57.5%0.0%

See Trefis Trade Ideas for more.

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1FTELFitell1068.4%-96.0%
2WOLFWolfspeed886.6%231.8%
3WHLRWheeler Real Estate Investment Trust404.4%-99.7%
4MNDRMobile-health Network Solutions388.0%-71.1%
5QUREuniQure329.5%236.4%
6NUAINew Era Energy & Digital311.7% 
7BQBoqii208.5%153.9%
8DVLTDatavault AI180.5% 
9DFLIDragonfly Energy132.9%-76.4%
10SHFSSHF130.9%-18.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1WOKWORK Medical Technology-91.5%-98.5%
2KALAKala Bio-89.0%-70.5%
3MLTXMoonLake Immunotherapeutics-88.6%-88.5%
4SDMSmart Digital-87.5%-83.8%
5NRIMNorthrim BanCorp-76.1%14.0%
6IOBTIO Biotech-75.5%-60.3%
7ZYBTZhengye Biotechnology-74.9% 
8AMBIAmbipar Emergency Response-74.0%-78.8%
9FGLFounder-63.8%-64.3%
10BINIBollinger Innovations-63.6%-100.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical13709.5%13709.5%
2TNFATNF Pharmaceuticals7529.9%-95.9%
3QMMMQMMM2749.6%9228.1%
4WOLFWolfspeed1757.1%231.8%
5EAFGrafTech International1199.0%-24.2%
6SEGGLottery.com646.7%-7.9%
7SLNHSoluna435.8%20.0%
8PTNMPitanium433.3% 
9NUAINew Era Energy & Digital395.6% 
10BREABrera380.3%3593.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1BINIBollinger Innovations-96.1%-100.0%
2WOKWORK Medical Technology-90.8%-98.5%
3CJETChijet Motor-90.3%-92.7%
4MLTXMoonLake Immunotherapeutics-88.6%-88.5%
5YAASYouxin Technology-85.8%-98.9%
6ATYRaTyr Pharma-85.1%-78.0%
7CURXCuranex Pharmaceuticals-84.9%28.8%
8YYGHYY-84.6%-80.3%
9NEONNeonode-84.6%-58.7%
10SDMSmart Digital-82.5%-83.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1FTELFitell1068.4%-96.0%
2WOLFWolfspeed886.6%231.8%
3WHLRWheeler Real Estate Investment Trust404.4%-99.7%
4MNDRMobile-health Network Solutions388.0%-71.1%
5QUREuniQure329.5%236.4%
6NUAINew Era Energy & Digital311.7% 
7BQBoqii208.5%153.9%
8DVLTDatavault AI180.5% 
9DFLIDragonfly Energy132.9%-76.4%
10SHFSSHF130.9%-18.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1WOKWORK Medical Technology-91.5%-98.5%
2KALAKala Bio-89.0%-70.5%
3MLTXMoonLake Immunotherapeutics-88.6%-88.5%
4SDMSmart Digital-87.5%-83.8%
5NRIMNorthrim BanCorp-76.1%14.0%
6IOBTIO Biotech-75.5%-60.3%
7ZYBTZhengye Biotechnology-74.9% 
8AMBIAmbipar Emergency Response-74.0%-78.8%
9FGLFounder-63.8%-64.3%
10BINIBollinger Innovations-63.6%-100.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Sinovac Biotech

Financials

SVAVRTXEDITINFIQSRNESTAMedian
NameSinovac .Vertex P.Editas M.Infinity.Sorrento.Starton . 
Mkt Price-395.313.52---199.41
Mkt Cap-101.50.3---50.9
Rev LTM51111,41939--0275
Op Inc LTM216-199-161---11-86
FCF LTM3523,500-205---352
FCF 3Y Avg1271,984-182---127
CFO LTM4793,846-201---479
CFO 3Y Avg1752,324-177---175

Growth & Margins

SVAVRTXEDITINFIQSRNESTAMedian
NameSinovac .Vertex P.Editas M.Infinity.Sorrento.Starton . 
Rev Chg LTM107.5%10.5%-42.0%---10.5%
Rev Chg 3Y Avg110.6%11.0%55.3%---55.3%
Rev Chg Q303.7%12.1%597.5%---303.7%
QoQ Delta Rev Chg LTM93.2%2.9%8.6%---8.6%
Op Mgn LTM42.3%-1.7%-413.4%----1.7%
Op Mgn 3Y Avg30.0%26.5%-616.5%---26.5%
QoQ Delta Op Mgn LTM24.2%2.0%164.9%---24.2%
CFO/Rev LTM93.9%33.7%-517.6%---33.7%
CFO/Rev 3Y Avg37.7%22.5%-538.7%---22.5%
FCF/Rev LTM68.9%30.6%-526.8%---30.6%
FCF/Rev 3Y Avg27.1%19.2%-552.8%---19.2%

Valuation

SVAVRTXEDITINFIQSRNESTAMedian
NameSinovac .Vertex P.Editas M.Infinity.Sorrento.Starton . 
Mkt Cap-101.50.3---50.9
P/S-8.97.6---8.3
P/EBIT-23.1-1.3---10.9
P/E-27.9-1.3---13.3
P/CFO-26.4-1.5---12.5
Total Yield-3.6%-79.7%----38.1%
Dividend Yield-0.0%0.0%---0.0%
FCF Yield 3Y Avg-2.1%-61.3%----29.6%
D/E-0.00.1---0.0
Net D/E--0.0-0.5----0.3

Returns

SVAVRTXEDITINFIQSRNESTAMedian
NameSinovac .Vertex P.Editas M.Infinity.Sorrento.Starton . 
1M Rtn-1.1%37.0%---19.0%
3M Rtn--11.2%60.0%---24.4%
6M Rtn--18.5%203.4%---92.5%
12M Rtn--14.6%1.1%----6.7%
3Y Rtn-36.5%-71.2%----17.4%
1M Excs Rtn--1.6%30.4%---14.4%
3M Excs Rtn--18.6%52.6%---17.0%
6M Excs Rtn--39.1%162.2%---61.6%
12M Excs Rtn--30.8%-12.6%----21.7%
3Y Excs Rtn--39.2%-150.7%----95.0%

Financials

$ Mil | FY: 12/312020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Period End12/31/20209/30/20206/30/20203/31/202012/31/20199/30/20196/30/20193/31/201912/31/20189/30/20186/30/20183/31/2018
Filing Date4/22/202112/7/20208/28/20206/30/20204/30/202011/18/20198/16/20197/11/20194/29/201911/18/201911/8/20187/11/2019
Key Financials Quarterly            
Total Revenue32711552158164643753547547
Ebitda200282-731162362181617
Operating Income19728-0-929142150161415
Net Income10911-4-6238122-1968
EPS1.090.10-0.05-0.070.220.060.110.01-0.030.120.100.15
Key Financials TTM            
Total Revenue TTM511264213225246218208219230208183109
Ebitda TTM2225341627647504353625123
Operating Income TTM2164834556940433545554518
Net Income TTM110252137452122152227226
Growth Rates Quarterly            
Total Revenue Growth303.7%79.4%-18.3%-57.9%52.4%19.3%-14.8%-22.8%69.7%87.7%5357.7%332.2%
EBITDA Growth547.2%73.3%-91.8%-215.1%1394.1%-12.8%46.6%-61.5%-81.3%145.5%229.4%6699.6%
Operating Income Growth582.6%99.2%-100.8%-277.3%10246.6%-14.9%52.5%-66.7%-97.2%157.2%200.8%970.3%
Net Income Growth369.2%43.2%-130.9%-427.7%2091.0%-12.1%112.2%-78.6%-126.2%176.5%159.9%538.7%
Margins Quarterly            
EBITDA Margin61.1%24.0%3.6%-48.2%38.1%24.8%35.9%17.6%3.9%34.0%20.9%35.3%
Operating Income Margin60.2%24.1%-0.3%-57.4%35.6%21.7%32.9%13.6%0.5%30.4%18.4%31.6%
Net Income Margin33.2%9.7%-7.2%-38.1%28.6%12.1%19.0%4.9%-2.2%16.4%7.6%17.7%
Cash & Debt            
Total Cash1,176184177187203176171168177-88-
Total Debt136118932620192021140290
Net Debt / (Cash)-1,040-66-84-161-183-157-150-147-163--59-
Cash Flows Quarterly            
FCF from Operations481142-18261210-9813-8-5
Cash Flows TTM            
FCF from Operations TTM479252230392022482-11-9
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-47.1%-0.5%-42.0%211.6%67.0%82.7%16.0%0.7%-50.0%-
Return on Invested Capital (ROIC) TTM            
ROIC TTM-24.2%22.2%70.9%116.2%46.8%41.0%30.7%53.0%-42.0%-

Short Interest

Short Interest: As Of Date9152025
Short Interest: Shares Quantity82,955
Short Interest: % Change Since 83120250.0%
Average Daily Volume0
Days-to-Cover Short Interest999.99
Basic Shares Quantity98,897,498
Short % of Basic Shares0.1%

SEC Filings

Expand for More

Report DateFiling DateFiling
630202481620246-K 6/30/2024
12312023429202420-F 12/31/2023
630202381520236-K 6/30/2023
12312022501202320-F 12/31/2022
6302022122920226-K 6/30/2022
12312021429202220-F 12/31/2021
6302021123020216-K 6/30/2021
12312020422202120-F 12/31/2020
9302020120720206-K 9/30/2020
630202082820206-K 6/30/2020
331202063020206-K 3/31/2020
12312019430202020-F 12/31/2019
9302019111820196-K 9/30/2019
630201981620196-K 6/30/2019
331201971120196-K 3/31/2019
12312018429201920-F 12/31/2018

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.